Revenio Group Oyj (LON:0KFH)

London flag London · Delayed Price · Currency is GBP · Price in EUR
20.82
-1.88 (-8.29%)
Jan 21, 2026, 4:37 PM GMT
Market Cap325.42M -49.1%
Revenue (ttm)96.96M +4.4%
Net Income13.72M -17.7%
EPS0.51 -17.7%
Shares Out n/a
PE Ratio23.72
Forward PE16.60
Dividend0.35 (1.67%)
Ex-Dividend DateApr 11, 2025
Volume152,500
Open21.00
Previous Close22.70
Day's Range20.82 - 21.00
52-Week Range13.46 - 29.15
Beta1.38
Analystsn/a
Price Targetn/a
Earnings DateApr 28, 2026

About Revenio Group Oyj

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by vet... [Read more]

Industry Medical - Equipment & Services
Sector Healthcare
Founded 2001
Employees 246
Stock Exchange London Stock Exchange
Ticker Symbol 0KFH

Financial Performance

In 2025, Revenio Group Oyj's revenue was 109.85 million, an increase of 5.80% compared to the previous year's 103.82 million. Earnings were 17.41 million, a decrease of -5.87%.

Financial numbers in EUR Financial Statements

News

Revenio Group Oyj Earnings Call Transcript: Q1 2026

Q1 saw 8.4% FX-adjusted sales growth, strong U.S. and Europe performance, but lower operating profit due to Visionix transaction costs. The Visionix acquisition expands the addressable market and product portfolio, with significant synergies and a rights issue planned for H2.

4 weeks ago - Transcripts

Revenio Group Oyj Quarterly report: Q1 2026

Revenio Group Oyj has published its Q1 2026 quarterly earnings report on April 28, 2026.

4 weeks ago - Filings

Revenio Group Oyj Slides: Q1 2026

Revenio Group Oyj has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.

4 weeks ago - Filings

Revenio Group Oyj Transcript: M&A announcement

The merger creates a leading ophthalmic diagnostics company with a EUR 2.5 billion accessible market, targeting EUR 20 million in synergies and 25% EBITDA margin by 2028-2029. Integration is structured for rapid synergy capture, with strong shareholder and leadership commitment.

6 weeks ago - Transcripts

Revenio Group Oyj Slides: M&A announcement

Revenio Group Oyj has posted slides in relation to its latest quarterly earnings report, which was published on April 13, 2026.

6 weeks ago - Filings

Revenio Group Oyj Press release: M&A announcement

Revenio Group Oyj issued a press release on April 13, 2026, disclosing material business information to investors.

6 weeks ago - Filings

Revenio Group Oyj Earnings Call Transcript: Q4 2025

Q4 and full-year 2025 saw strong sales growth, record US performance, and robust cash flow, despite margin pressure from tariffs and delayed price increases. 2026 guidance anticipates 8%-15% sales growth, with profitability supported by ongoing price adjustments and a strong product pipeline.

3 months ago - Transcripts

Revenio Group Oyj Annual report: Q4 2025

Revenio Group Oyj has published its Q4 2025 annual report on February 11, 2026.

3 months ago - Filings

Revenio Group Oyj Quarterly report: Q4 2025

Revenio Group Oyj has published its Q4 2025 quarterly earnings report on February 11, 2026.

3 months ago - Filings

Revenio Group Oyj Slides: Q4 2025

Revenio Group Oyj has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 11, 2026.

3 months ago - Filings

Revenio Group Oyj Earnings Call Transcript: Q3 2025

Q3 delivered 8.1% sales growth and 9.1% higher operating profit, led by strong European and U.S. performance in screening devices and software. Guidance remains unchanged, with Q4 expected to be the strongest quarter. New product launches and robust financials support a positive outlook.

7 months ago - Transcripts

Revenio Group Oyj Quarterly report: Q3 2025

Revenio Group Oyj has published its Q3 2025 quarterly earnings report on October 30, 2025.

7 months ago - Filings

Revenio Group Oyj Slides: Q3 2025

Revenio Group Oyj has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 30, 2025.

7 months ago - Filings

Revenio Group Oyj Earnings Call Transcript: Q2 2025

Q2 saw 4.2% reported sales growth (7.2% currency-adjusted), with all regions and product categories contributing. Gross margin exceeded 70%, and adjusted operating profit rose ~10% in Q2. Tariff impacts are being managed with planned price increases as inventory runs out.

10 months ago - Transcripts

Revenio Group Oyj Quarterly report: Q2 2025

Revenio Group Oyj has published its Q2 2025 quarterly earnings report on August 7, 2025.

10 months ago - Filings

Revenio Group Oyj Slides: Q2 2025

Revenio Group Oyj has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 7, 2025.

10 months ago - Filings